A new clinical trial backed by the National Institutes of Health suggests that semaglutide — the GLP-1 medication better known by brand names like Ozempic and Wegovy — may help people with alcohol use disorder cut back on heavy drinking when combined with cognitive behavioral therapy. The findings, released in late April 2026, add to a growing body of research hinting that GLP-1 drugs influence more than appetite alone.
What the New NIH Trial Found
Researchers enrolled adults who met criteria for both alcohol use disorder and obesity. Participants received cognitive behavioral therapy (CBT) for alcohol use, and a subset also received semaglutide. According to the NIH summary, those who combined semaglutide with CBT reported significantly fewer heavy drinking days than people receiving therapy alone.
Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as four or more drinks on any day for women and five or more for men. Reducing those episodes — not just total drinks — is a key target in alcohol use disorder treatment because heavy drinking days carry the highest medical and social risk.
Why This Matters
Alcohol use disorder affects an estimated 28.9 million Americans aged 12 and older, according to the 2023 National Survey on Drug Use and Health. Only a fraction receive medication treatment, even though the FDA has approved three drugs (naltrexone, acamprosate, and disulfiram) for the condition. Stigma, side effects, and access barriers all play a role.
If GLP-1 medicines — already prescribed to tens of millions of people for diabetes and weight management — turn out to also help people drink less, it could meaningfully widen the pool of effective options.
How Might Semaglutide Influence Drinking?
GLP-1 receptors are found throughout the brain’s reward circuitry, including the nucleus accumbens and ventral tegmental area — regions involved in cravings for food, alcohol, and other substances. Animal studies dating back more than a decade have shown that GLP-1 drugs can reduce voluntary alcohol intake in rodents and primates.
Human evidence has been catching up. A 2025 randomized trial published in JAMA Psychiatry reported that low-dose semaglutide reduced drinks per drinking day and weekly alcohol craving scores in adults with alcohol use disorder, even at doses lower than those used for weight loss. The new NIH-supported study extends those findings by pairing the drug with structured psychotherapy.
Proposed Mechanisms
- Reward signaling: GLP-1 activation appears to blunt dopamine release in response to alcohol, dampening the rewarding “buzz.”
- Craving suppression: Functional MRI studies suggest GLP-1 drugs reduce activation in brain regions linked to cue-induced cravings.
- Stress-axis modulation: Early research indicates effects on stress hormones that often drive relapse.
Researchers emphasize these mechanisms are still being mapped — and that not every patient will respond.
Why Add Cognitive Behavioral Therapy?
Cognitive behavioral therapy remains a cornerstone of alcohol use disorder treatment because it teaches durable skills: identifying drinking triggers, restructuring thoughts that lead to use, and building coping strategies. Reviews summarized by the Substance Abuse and Mental Health Services Administration (SAMHSA) consistently rank CBT among the most effective psychosocial interventions for alcohol use.
Medication alone rarely produces lasting change in substance use disorders. Combining a biological tool with a behavioral one — sometimes called medication-assisted treatment — mirrors successful models used for opioid and tobacco use disorders.
Important Caveats Before Anyone Asks Their Doctor
Even with positive results, several limits temper enthusiasm:
- Not an approved use. Semaglutide is not FDA-approved to treat alcohol use disorder. Any prescription for that purpose would be off-label.
- Population studied was specific. Participants in this NIH trial had both alcohol use disorder and obesity. Whether the benefit extends to people without obesity is still being studied.
- Side effects are real. Nausea, vomiting, constipation, gallbladder issues, and rare cases of pancreatitis can occur. The FDA has also flagged ongoing surveillance for psychiatric symptoms.
- Cost and access. GLP-1 drugs remain expensive and intermittently in short supply.
- Longer trials are needed. Most studies so far run 6 months or less. Sustained drinking reduction at one and two years is still being measured.
Who Should Talk to a Clinician?
Anyone who recognizes their drinking pattern in NIAAA’s definitions of heavy drinking, or who has tried to cut back unsuccessfully, can benefit from a conversation with a primary care provider or addiction specialist. Effective options — including FDA-approved medications and evidence-based therapies — already exist, and access has expanded through telehealth.
The Bigger Picture: GLP-1s Beyond Weight Loss
Research is rapidly exploring whether GLP-1 drugs can help with cravings across substance use disorders, including nicotine and stimulants, as well as binge eating disorder. The American Society of Addiction Medicine has called for larger, longer trials before clinical guidelines change.
The semaglutide-plus-CBT finding doesn’t mean GLP-1 drugs are a cure for problem drinking. It does suggest, however, that the next generation of addiction treatment may look very different — combining metabolic medicines, brain-targeted therapies, and structured behavioral support in ways previous decades couldn’t.
Practical Takeaways
- If you’re concerned about your drinking, screening tools like the AUDIT-C are free, brief, and a useful starting point with a clinician.
- Evidence-based treatments for alcohol use disorder already exist and are underused — ask about them before chasing off-label options.
- For people already taking GLP-1 medications for diabetes or weight, any apparent decrease in alcohol cravings is worth mentioning to your prescriber.
- Recovery is a process. Medication, therapy, peer support (such as SMART Recovery or AA), and lifestyle changes all play complementary roles.
Research suggests that medications once considered narrowly metabolic may have far broader applications. As trials continue, the conversation around alcohol use disorder is shifting from willpower to neurobiology — and that shift is overdue.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.